Announcements Trials

Browse Landscape

Phase

Status

Terminated 4 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 363 Bortezomib 232 Lenalidomide 202 Cyclophosphamide 174 Melphalan 154 Calcium Dobesilate 107 Peripheral Blood Stem Cell Transplantation 92 fludarabine phosphate 84 Thalidomide 81 Filgrastim 71 carfilzomib 68 pomalidomide 66 Granulocyte Colony-Stimulating Factor 60 Mycophenolic Acid 59 Busulfan 57 daratumumab 55 Whole-Body Irradiation 54 Tacrolimus 51 ixazomib 50 Prednisone 50 Cyclosporine 49 fludarabine 46 Antilymphocyte Serum 35 Etoposide 30 dexamethasone acetate 29 Methotrexate 29 plerixafor 27 Radiotherapy 26 Doxorubicin 26 dexamethasone 21-phosphate 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Multiple Myeloma × melflufen × Clear all

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡